| Assessment Status | Rapid Review Complete |
| HTA ID | 23006 |
| Drug | Icosapent ethyl |
| Brand | Vazkepa® |
| Indication | Icosapent ethyl (Vazkepa®) is indicated to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (?150 mg/dL [?1.7 mmol/L] and established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor. |
| Assessment Process | |
| Rapid review commissioned | 10/02/2023 |
| Rapid review completed | 10/03/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of icosapent ethyl compared with the current standard of care. |
